Geneos Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Geneos Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-68	Closed	-$550	–	2504
2025 Q2	$550	Buy	+68	New	+$513	﹤0.01%	3095
2022 Q3	–	Sell	-200	Closed	–	–	2020
2022 Q2	$0	Hold	200	–	–	﹤0.01%	2583
2022 Q1	$0	Buy	+200	New	+$886	﹤0.01%	2748
2021 Q4	–	Sell	-201	Closed	-$1K	–	2765
2021 Q3	$1K	Hold	201	–	–	﹤0.01%	2708
2021 Q2	$1K	Sell	201 -321	-61%	-$1.82K	﹤0.01%	2727
2021 Q1	$2K	Buy	522 +322	+161%	+$1.78K	﹤0.01%	2860
2020 Q4	$1K	Buy	+200	New	+$886	﹤0.01%	2759
2019 Q3	–	Sell	-200	Closed	-$1K	–	2489
2019 Q2	$1K	Hold	200	–	–	﹤0.01%	2367
2019 Q1	$2K	Hold	200	–	–	﹤0.01%	2210
2018 Q4	$2K	Hold	200	–	–	﹤0.01%	2169
2018 Q3	$4K	Hold	200	–	–	﹤0.01%	2092
2018 Q2	$3K	Buy	+200	New	+$3.51K	﹤0.01%	2020

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Geneos Wealth Management's AMRX Position: Q3 2025 in Review

Geneos Wealth Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2025, closing a stake of 68 shares — an estimated $550 sold.

Geneos Wealth Management first reported a position in AMRX in Q2 2018 and held it in 12 quarters. The position peaked at $4K in Q3 2018. 248 funds tracked by Wall St. Rank hold AMRX as of Q3 2025.

Geneos Wealth Management reported no remaining Amneal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Geneos Wealth Management sold 68 Amneal Pharmaceuticals shares in Q3 2025, an estimated $550.
Geneos Wealth Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 12 quarters.
Geneos Wealth Management's Amneal Pharmaceuticals position peaked at $4K in Q3 2018.
248 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.